{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:37:30Z","timestamp":1762252650127},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology (MOST)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001869","name":"Academia Sinica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008761","name":"Taiwan Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008761","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ejmech.2017.12.036","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T23:45:59Z","timestamp":1513122359000},"page":"626-634","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Synthesis of (3 S ,4 S ,5 S )-trihydroxylpiperidine derivatives as enzyme stabilizers to improve therapeutic enzyme activity in Fabry patient cell lines"],"prefix":"10.1016","volume":"144","author":[{"given":"Huang-Yi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay-Der","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiao-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Chieh","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chieh","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2017.12.036_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1875397301004010050","article-title":"Fabry disease \u2013 current treatment and new drug development","volume":"4","author":"Motabar","year":"2010","journal-title":"Curr. Chem. Genom."},{"key":"10.1016\/j.ejmech.2017.12.036_bib2","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1021\/cb500143h","article-title":"Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human \u03b1-galactosidase A: pharmacological chaperoning efficacy on Fabry disease mutants","volume":"9","author":"Yu","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2017.12.036_bib3","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.cca.2010.03.009","article-title":"Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry","volume":"411","author":"Dajnoki","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2017.12.036_bib4","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2017.12.036_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2017.12.036_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2008.10.004","article-title":"A\u00a0retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease","volume":"96","author":"B\u00e9nichou","year":"2009","journal-title":"Mol. Gen. Metab"},{"key":"10.1016\/j.ejmech.2017.12.036_bib7","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood-brain barrier","volume":"14","author":"Begley","year":"2008","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2017.12.036_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A\u00a0phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2017.12.036_bib9","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2017.12.036_bib10","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/mt.2011.271","article-title":"Co-administration with the pharmacological chaperone AT1001 increases recombinant human \u03b1-galactosidase A tissue uptake and improves substrate reduction in Fabry mice","volume":"20","author":"Benjamin","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2017.12.036_bib11","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts","volume":"17","author":"Porto","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2017.12.036_bib12","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1016\/j.bmcl.2008.06.086","article-title":"Correlation of inhibitor effects on enzyme activity and thermal stability for the integral membrane protein fatty acid amide hydrolase","volume":"18","author":"Slaymakera","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2017.12.036_bib13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/emboj\/19.6.1195","article-title":"Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain","volume":"19","author":"Barbato","year":"2000","journal-title":"Eur. Mol. Biol. Organ. J"},{"key":"10.1016\/j.ejmech.2017.12.036_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040776","article-title":"The pharmacological chaperone AT2220 increases recombinant human acid \u03b1-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease","volume":"7","author":"Khanna","year":"2012","journal-title":"PLos One"},{"key":"10.1016\/j.ejmech.2017.12.036_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102092","article-title":"The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease","volume":"9","author":"Khanna","year":"2014","journal-title":"PLos One"},{"key":"10.1016\/j.ejmech.2017.12.036_bib16","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/mt.2015.87","article-title":"Coformulation of a novel human \u03b1-Galactosidase A with the pharmacological chaperone AT1001 leads to improved substrate reduction in Fabry Mice","volume":"23","author":"Xu","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2017.12.036_bib17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejmech.2016.07.025","article-title":"Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency","volume":"123","author":"Cheng","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.036_bib18","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1002\/ejoc.201001045","article-title":"Straightforward synthesis of diverse 1-deoxyazapyranosides via stereocontrolled nucleophilic additions to six-membered cyclic nitrones","author":"Chan","year":"2010","journal-title":"Eur. J. Org Chem."},{"key":"10.1016\/j.ejmech.2017.12.036_bib19","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.tetlet.2004.12.119","article-title":"Straightforward synthesis of enantiopure 2-aminomethyl and 2-hydroxymethyl pyrrolidines with complete stereocontrol","volume":"46","author":"Marradi","year":"2005","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2017.12.036_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2016.10.004","article-title":"Rapid preparation of (3R,4R,5R) polyhydroxylated pyrrolidine-based libraries to discover a pharmacological chaperone for treatment of Fabry disease","volume":"126","author":"Cheng","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2017.12.036_bib21","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1021\/jo802255t","article-title":"A\u00a0Short and convenient synthesis of 1-deoxymannojirimycin and N-oxy analogues from D-fructose","volume":"74","author":"Racine","year":"2009","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2017.12.036_bib22","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1021\/acs.orglett.5b01505","article-title":"Hydroxymethyl-branched polyhydroxylated indolizidines: Novel selective \u03b1-glucosidase inhibitors","volume":"17","author":"Boisson","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2017.12.036_bib23","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tet.2008.10.096","article-title":"A\u00a0convenient approach toward the synthesis of enantiopure isomers of DMDP and ADMDP","volume":"65","author":"Tsou","year":"2009","journal-title":"Tetrahedron"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417310486?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523417310486?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T18:11:00Z","timestamp":1589825460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523417310486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":23,"alternative-id":["S0223523417310486"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.12.036","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis of (3S,4S,5S)-trihydroxylpiperidine derivatives as enzyme stabilizers to improve therapeutic enzyme activity in Fabry patient cell lines","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2017.12.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}